Compounds > pregna-4-17-diene-3-16-dione

pregna-4-17-diene-3-16-dione and Cholestasis

pregna-4-17-diene-3-16-dione has been researched along with Cholestasis* in 1 studies

Other Studies

1 other study(ies) available for pregna-4-17-diene-3-16-dione and Cholestasis

Article	Year
Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo. British journal of pharmacology, 2018, Volume: 175, Issue:5 The aim of this study was to investigate the ameliorative effects of corilagin on intrahepatic cholestasis induced by regulating liver farnesoid X receptor (FXR)-associated pathways in vitro and in vivo.. Cellular and animal models were treated with different concentrations of corilagin. In the cellular experiments, FXR expression was up-regulated by either lentiviral transduction or GW4064 treatment and down-regulated by either siRNA technology or treatment with guggulsterones. Real-time PCR and Western blotting were employed to detect the mRNA and protein levels of FXR, SHP1, SHP2, UGT2B4, BSEP, CYP7A1, CYP7B1, NTCP, MRP2 and SULT2A1. Immunohistochemistry was used to examine the expression of BSEP in liver tissues. Rat liver function and pathological changes in hepatic tissue were assessed using biochemical tests and haematoxylin and eosin staining.. Corilagin increased the mRNA and protein levels of FXR, SHP1, SHP2, UGT2B4, BSEP, MRP2 and SULT2A1, and decreased those of CYP7A1, CYP7B1 and NTCP. After either up- or down-regulating FXR using different methods, corilagin could still increase the mRNA and protein levels of FXR, SHP1, SHP2, UGT2B4, BSEP, MRP2 and SULT2A1 and decrease the protein levels of CYP7A1, CYP7B1 and NTCP, especially when administered at a high concentration. Corilagin also exerted a notable effect on the pathological manifestations of intrahepatic cholestasis, BSEP staining in liver tissues and liver function.. Corilagin exerts a protective effect in hepatocytes and can prevent the deleterious activities of intrahepatic cholestasis by stimulating FXR-associated pathways. Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Cell Survival; Cells, Cultured; Cholestasis; Cholesterol 7-alpha-Hydroxylase; Cytochrome P450 Family 7; Dexamethasone; Down-Regulation; Glucosides; Glucuronosyltransferase; Humans; Hydrolyzable Tannins; Isoxazoles; Liver; Male; Organic Anion Transporters, Sodium-Dependent; Pregnenediones; Primary Cell Culture; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Small Interfering; Steroid Hydroxylases; Sulfotransferases; Symporters; Up-Regulation; Ursodeoxycholic Acid	2018

Article

Year

Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo.

British journal of pharmacology, 2018, Volume: 175, Issue:5

The aim of this study was to investigate the ameliorative effects of corilagin on intrahepatic cholestasis induced by regulating liver farnesoid X receptor (FXR)-associated pathways in vitro and in vivo.. Cellular and animal models were treated with different concentrations of corilagin. In the cellular experiments, FXR expression was up-regulated by either lentiviral transduction or GW4064 treatment and down-regulated by either siRNA technology or treatment with guggulsterones. Real-time PCR and Western blotting were employed to detect the mRNA and protein levels of FXR, SHP1, SHP2, UGT2B4, BSEP, CYP7A1, CYP7B1, NTCP, MRP2 and SULT2A1. Immunohistochemistry was used to examine the expression of BSEP in liver tissues. Rat liver function and pathological changes in hepatic tissue were assessed using biochemical tests and haematoxylin and eosin staining.. Corilagin increased the mRNA and protein levels of FXR, SHP1, SHP2, UGT2B4, BSEP, MRP2 and SULT2A1, and decreased those of CYP7A1, CYP7B1 and NTCP. After either up- or down-regulating FXR using different methods, corilagin could still increase the mRNA and protein levels of FXR, SHP1, SHP2, UGT2B4, BSEP, MRP2 and SULT2A1 and decrease the protein levels of CYP7A1, CYP7B1 and NTCP, especially when administered at a high concentration. Corilagin also exerted a notable effect on the pathological manifestations of intrahepatic cholestasis, BSEP staining in liver tissues and liver function.. Corilagin exerts a protective effect in hepatocytes and can prevent the deleterious activities of intrahepatic cholestasis by stimulating FXR-associated pathways.

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Cell Survival; Cells, Cultured; Cholestasis; Cholesterol 7-alpha-Hydroxylase; Cytochrome P450 Family 7; Dexamethasone; Down-Regulation; Glucosides; Glucuronosyltransferase; Humans; Hydrolyzable Tannins; Isoxazoles; Liver; Male; Organic Anion Transporters, Sodium-Dependent; Pregnenediones; Primary Cell Culture; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Small Interfering; Steroid Hydroxylases; Sulfotransferases; Symporters; Up-Regulation; Ursodeoxycholic Acid

2018